Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NKTR
stocks logo

NKTR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.67M
-66.85%
-2.531
-662.54%
9.68M
-7.44%
-2.126
-40.94%
9.33M
-16.47%
-2.294
-22.24%
Estimates Revision
The market is revising Upward the revenue expectations for Nektar Therapeutics (NKTR) for FY2025, with the revenue forecasts being adjusted by 3.72% over the past three months. During the same period, the stock price has changed by 43.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-18.14%
In Past 3 Month
Stock Price
Go Up
up Image
+43.58%
In Past 3 Month
Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 57.690
sliders
Low
30.00
Averages
93.86
High
120.00
Current: 57.690
sliders
Low
30.00
Averages
93.86
High
120.00
Citi
NULL
to
Buy
initiated
$102
2025-11-26
Reason
Citi
Price Target
$102
2025-11-26
initiated
NULL
to
Buy
Reason
Citi initiated coverage of Nektar with a Buy rating and $102 price target. Citi also opened a "positive 90-day catalyst watch" on Nektar ahead of the Phase 2b alopecia areata data expected in December. The firm believes data for rezpegaldesleukin in atopic dermatitis "look competitive" in crowded field. It sees an "asymmetrical upside" opportunity for the shares into the December readout.
Jefferies
Buy
upgrade
$99 -> $121
2025-11-26
Reason
Jefferies
Price Target
$99 -> $121
2025-11-26
upgrade
Buy
Reason
Jefferies raised the firm's price target on Nektar to $121 from $99 and keeps a Buy rating on the shares. With "relatively low expectations" going into Nektar's Rezpeg reporting Phase 2b topline data in Alopecia Areata in December, the firm sees "significant upside potential and limited downside" given Rezpeg's novel mechanism of action, clean safety profile and durability potential, the analyst tells investors. The firm is adding AA to its model with 20% odds of success and about $300M in estimated peak sales.
Jefferies
Roger Song
Buy
maintain
$69 -> $99
2025-09-18
Reason
Jefferies
Roger Song
Price Target
$69 -> $99
2025-09-18
maintain
Buy
Reason
Jefferies analyst Roger Song raised the firm's price target on Nektar to $99 from $69 and keeps a Buy rating on the shares after the company announced data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. The positive patient-reported outcome assessments add further support for rezpegaldesleukin's benefit in atopic dermatitis and complimented the efficacy data reported in June, the analyst tells investors in a research note. Jefferies upped the drug's probability of success to 55% from 45%.
Oppenheimer
Oppenheimer
Outperform
upgrade
$90 -> $98
2025-08-08
Reason
Oppenheimer
Oppenheimer
Price Target
$90 -> $98
2025-08-08
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on Nektar to $98 from $90 and keeps an Outperform rating on the shares following quarterly results. The firm notes Q2 marks an important milestone for Nektar, as the company reported positive topline results from the Phase 2b REZOLVE-AD study of rezpeg in atopic dermatitis. Oppenheimer anticipates additional updates in the coming months, including data presentation in the second half of the year at a medical conference; alopecia areata topline results in December; and maintenance data from REZOLVE-AD in Q1 2026.
B. Riley
NULL -> Buy
upgrade
$60 -> $85
2025-07-08
Reason
B. Riley
Price Target
$60 -> $85
2025-07-08
upgrade
NULL -> Buy
Reason
B. Riley raised the firm's price target on Nektar to $85 from $60 and keeps a Buy rating on the shares.
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
$120
2025-06-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$120
2025-06-24
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Nektar to $120 from $6.50 and keeps a Buy rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nektar Therapeutics (NKTR.O) is -6.13, compared to its 5-year average forward P/E of -2.89. For a more detailed relative valuation and DCF analysis to assess Nektar Therapeutics 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.89
Current PE
-6.13
Overvalued PE
-0.77
Undervalued PE
-5.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.15
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.13
Undervalued EV/EBITDA
-4.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.73
Current PS
0.00
Overvalued PS
21.62
Undervalued PS
-0.17
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1229.84% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NKTR News & Events

Events Timeline

(ET)
2025-11-09
12:21:17
Nektar unveils fresh findings from the REZOLVE-AD study at ACAAI
select
2025-11-06 (ET)
2025-11-06
16:23:12
Nektar announces Q3 adjusted EPS of $1.85, falling short of consensus estimate of $2.79
select
2025-10-17 (ET)
2025-10-17
14:11:56
Nektar Speculation Featured in Betaville Update
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-27NASDAQ.COM
Jefferies Upholds Buy Rating for Nektar Therapeutics (NKTR)

  • Analyst Recommendation: Jefferies has maintained a Buy recommendation for Nektar Therapeutics, with an average one-year price target of $95.73/share, indicating a potential upside of 58.63% from its current price of $60.35/share.

  • Institutional Ownership Growth: There has been a significant increase in institutional ownership of Nektar Therapeutics, with 218 funds reporting positions, a 78.69% increase in the last quarter, and total shares owned rising by 97.26% to 15,187K shares.

  • Projected Financials: Nektar Therapeutics is projected to achieve annual revenue of $100 million, reflecting a 59.87% increase, while the expected non-GAAP EPS is -1.19.

  • Bullish Sentiment: The put/call ratio for Nektar Therapeutics stands at 0.25, suggesting a bullish outlook among investors, with several firms significantly increasing their portfolio allocations in the company over the last quarter.

[object Object]
Preview
4.0
11-27NASDAQ.COM
Citigroup Begins Coverage of Nektar Therapeutics (NKTR) with a Buy Rating

  • Citigroup Coverage Initiation: On November 26, 2025, Citigroup began coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a "Buy" recommendation, projecting a 58.63% upside based on an average one-year price target of $95.73/share.

  • Institutional Ownership Growth: There has been a significant increase in institutional ownership of Nektar Therapeutics, with 218 funds reporting positions, a 78.69% rise in the last quarter, and total shares owned increasing by 97.26% to 15,187K shares.

  • Analyst Revenue and EPS Projections: Nektar Therapeutics is projected to achieve annual revenue of $100 million, reflecting a 59.87% increase, while the projected annual non-GAAP EPS is -1.19.

  • Bullish Market Sentiment: The put/call ratio for NKTR stands at 0.25, indicating a bullish outlook among investors, with notable increases in shareholdings from several key institutional investors.

[object Object]
Preview
6.0
11-27Benzinga
Citigroup Begins Coverage of Nektar Therapeutics with a Buy Rating and Sets Price Target at $102

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nektar Therapeutics (NKTR) stock price today?

The current price of NKTR is 57.69 USD — it has increased 0.98 % in the last trading day.

arrow icon

What is Nektar Therapeutics (NKTR)'s business?

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

arrow icon

What is the price predicton of NKTR Stock?

Wall Street analysts forecast NKTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTR is 93.86 USD with a low forecast of 30.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nektar Therapeutics (NKTR)'s revenue for the last quarter?

Nektar Therapeutics revenue for the last quarter amounts to 11.79M USD, decreased -51.13 % YoY.

arrow icon

What is Nektar Therapeutics (NKTR)'s earnings per share (EPS) for the last quarter?

Nektar Therapeutics. EPS for the last quarter amounts to -1.87 USD, decreased -29.70 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nektar Therapeutics (NKTR)'s fundamentals?

The market is revising Upward the revenue expectations for Nektar Therapeutics (NKTR) for FY2025, with the revenue forecasts being adjusted by 3.72% over the past three months. During the same period, the stock price has changed by 43.58%.
arrow icon

How many employees does Nektar Therapeutics (NKTR). have?

Nektar Therapeutics (NKTR) has 61 emplpoyees as of December 05 2025.

arrow icon

What is Nektar Therapeutics (NKTR) market cap?

Today NKTR has the market capitalization of 1.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free